Clinical Trials Logo

Clinical Trial Summary

The purpose of this studdy is to assess the effectiveness of a telegeriatric intervention


Clinical Trial Description

The patients were recruited from a cohort study in which the participants had previously signed an informed consent in which they allowed contact to participate in new studies, participants who met the inclusion criteria in the original database were recruited and signed an electronic informed consent of the new study. A comprehensive geriatric assessment was generated to assess whether they were candidates even due to changes in health status that could change over time since their last assessment, they were recruited until the expected sample size was obtained, and they were randomized, blinding the participants to belong to the intervention group (individualized care: geriatrics, psychology, physical activity and nutrition) or the control group (orientation in standardized health issues through audiovisual educational material) ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04747132
Study type Interventional
Source Universidad Iberoamericana A.C., Mexico
Contact
Status Completed
Phase N/A
Start date July 20, 2020
Completion date November 16, 2020

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04596956 - Safety and Efficacy of Sodium Bicarbonate Ringer Injection Phase 4
Recruiting NCT05135780 - The Quality of Life in Children at Social Risk, a Case Series Study Protocol
Not yet recruiting NCT04326114 - Effectiveness and Safety of Respiratory Training in the Prevention and Severity of COVID-19 N/A
Completed NCT06341348 - Effects of Case Management for Patients With Rheumatoid Arthritis in Taiwan N/A
Completed NCT04379258 - Analysis of Mortality of Critically Ill Patients With COVID-19
Not yet recruiting NCT05177666 - a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors
Completed NCT04897919 - Effectiveness and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for Treating Malaria Phase 4
Recruiting NCT05617859 - Lenvatinib for Advanced Bone and Soft Tissue Sarcoma Phase 2